Table III.
Interval from diagnosis of leukaemia to development of leukaemia cutis (LC)
| AML | ALL | CML | CLL | MDS | Total | |
|---|---|---|---|---|---|---|
| Skin lesions following systemic involvement, n (%) | 36 | 6 | 3 | 1 | 1 | 47 (84) |
| Duration, months, mean (range) | 11 (0.3–64) | 23.4 (0.7–38) | 8.6 (3–17) | 5.3 (5.3) | 11.7 (11.7) | 12.3 (0.3–64) |
| Concurrent occurrence, n (%) | 3 | 2 | 1 | 2 | 8 (14) | |
| Skin lesions preceding systemic involvement, n (%) | 1 | 1 (2) | ||||
| Duration, months, mean (range) | 1 (1) | 1 (1) |
AML: acute myelogenous leukaemia; ALL: acute lymphoblastic leukaemia; CML: chronic myeloid leukaemia; CLL: chronic lymphocytic leukaemia; MDS: myelodysplastic syndrome.